MIRA
INFORM REPORT
|
Report Date : |
06.03.2013 |
IDENTIFICATION DETAILS
|
Name : |
ALPA LABORATORIES LIMITED |
|
|
|
|
Registered Office : |
33/ 2, A.B. Road, Pigdamber Rao, Indore – 453446, Madhya Pradesh |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2012 |
|
|
|
|
Date of Incorporation : |
18.03.1988 |
|
|
|
|
Com. Reg. No.: |
10-004446 |
|
|
|
|
Capital Investment / Paid-up Capital : |
Rs.210.406 Millions |
|
|
|
|
CIN No.: [Company
Identification No.] |
L85195MP1988PLC004446 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
BPLA02074C |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AACCA8437C |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The company’s shares are listed on
stock exchange. |
|
|
|
|
Line of Business : |
Manufacturer and Trader of Pharmaceutical and Botanical Products. |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
B (32) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 3900000 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having a moderate track record. The profitability
of the company appears to be low and there is continuous dip in sales
turnover. However, trade relations are reported to be fair. Business is active.
Payments are reported to be slow but correct. The company can be considered for business dealings with slight
caution. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
India is developing into an open-market economy, yet traces
of its past autarkic policies remain. Economic liberalization, including industrial
deregulation, privatization of state-owned enterprises, and reduced controls on
foreign trade and investment, began in the early 1990s and has served to
accelerate the country's growth, which has averaged more than 7% per year since
1997. India's diverse economy encompasses traditional village farming, modern
agriculture, handicrafts, a wide range of modern industries, and a multitude of
services. Slightly more than half of the work force is in agriculture, but
services are the major source of economic growth, accounting for more than half
of India's output, with only one-third of its labor force. India has
capitalized on its large educated English-speaking population to become a major
exporter of information technology services and software workers. In 2010, the
Indian economy rebounded robustly from the global financial crisis - in large
part because of strong domestic demand - and growth exceeded 8% year-on-year in
real terms. However, India's economic growth in 2011 slowed because of persistently
high inflation and interest rates and little progress on economic reforms. High
international crude prices have exacerbated the government's fuel subsidy
expenditures contributing to a higher fiscal deficit, and a worsening current
account deficit. Little economic reform took place in 2011 largely due to
corruption scandals that have slowed legislative work. India's medium-term
growth outlook is positive due to a young population and corresponding low
dependency ratio, healthy savings and investment rates, and increasing
integration into the global economy. India has many long-term challenges that
it has not yet fully addressed, including widespread poverty, inadequate
physical and social infrastructure, limited non-agricultural employment
opportunities, scarce access to quality basic and higher education, and
accommodating rural-to-urban migration.
|
Source
: CIA |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
LOCATIONS
|
Registered Office/ Corporate Office/ Factory 1 : |
33/ 2, |
|
Tel. No.: |
91-731-4294567 |
|
Fax No.: |
91-731-4294444 |
|
E-Mail : |
|
|
Website: |
|
|
|
|
|
Factory 2 : |
481, Sector-III, Pithampur, District Dhar, Indore –
454775, Madhya Pradesh, India |
|
|
|
|
Marketing Office : |
1/C/803, 8th Floor, Prathamesh Vihar, 90 Foot Road, Thakur Complex, Kandivli (East), Mumbai – 400101, Maharashtra, India |
|
Tel No.: |
91-22-65104567 |
|
Fax No.: |
91-22-28700155 |
|
E-Mail Id : |
DIRECTORS
As on 31.03.2012
|
Name : |
Mr. Purushottam R. Patel |
|
Designation : |
Chairman and Managing Director |
|
Qualification : |
B.Sc. (Honors) |
|
Date of Appointment : |
18.03.1988 |
|
|
|
|
Name : |
Mr. Mahendra Singh Chawla |
|
Designation : |
Whole Time Director |
|
Date of Birth/Age : |
68 Years |
|
Qualification : |
B.Sc. |
|
Experience : |
43 Years |
|
Date of Appointment : |
18.03.1988 |
|
|
|
|
Name : |
Mr. Pravin C. Shah |
|
Designation : |
Whole Time Director |
|
Qualification : |
B.Sc. |
|
Date of Appointment : |
18.03.1988 |
|
|
|
|
Name : |
Mr. Sharad Chand Lunawat |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Devendra Baheti |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Krishna Das Malani |
|
Designation : |
Director |
KEY EXECUTIVES
|
Name : |
Mr. Hemant Jain |
|
Designation : |
Compliance Officer |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 31.12.2012
|
Category of Shareholder |
No. of Shares |
Percentage of
Holding |
|
(A) Shareholding
of Promoter and Promoter Group |
|
|
|
|
|
|
|
|
11438470 |
54.36 |
|
|
11438470 |
54.36 |
|
|
|
|
|
|
49900 |
0.24 |
|
|
49900 |
0.24 |
|
Total
shareholding of Promoter and Promoter Group (A) |
11488370 |
54.60 |
|
(B) Public
Shareholding |
|
|
|
|
|
|
|
|
|
|
|
|
682782 |
3.25 |
|
|
|
|
|
|
5499402 |
26.14 |
|
|
3128220 |
14.87 |
|
|
241826 |
1.15 |
|
|
9266 |
0.04 |
|
|
232560 |
1.11 |
|
|
9552230 |
45.40 |
|
Total Public
shareholding (B) |
9552230 |
45.40 |
|
Total (A)+(B) |
21040600 |
100.00 |
|
(C) Shares held
by Custodians and against which Depository Receipts have been issued |
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
Total (A)+(B)+(C) |
21040600 |
0.00 |
(1) Indian
Individuals / Hindu Undivided Family
Individual shareholders holding nominal
share capital up to Rs.0.100 millionBUSINESS DETAILS
|
Line of Business : |
Manufacturer and Trader of Pharmaceutical and Botanical Products. |
||||||||||||||||
|
|
|
||||||||||||||||
|
Products : |
|
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
·
State Bank of Indore, Yeshwant Niwas Road Branch,
Indore – 452 001, Madhya Pradesh, India ·
Bank of baroda, A. B. Road branch, Indore – 452001,
Madhya Pradesh, India |
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
(Rs.
In Millions)
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Statutory Auditors : |
|
|
Name : |
C.H. Padliya and Company Chartered Accountants |
|
Address : |
Pigdamber, Rau, |
|
|
|
|
Cost Auditors : |
|
|
Name : |
M. P. Turakhia and Associates Practicing Cost Accountants |
CAPITAL STRUCTURE
As on: 31.03.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
25000000 |
Equity Shares |
Rs.10/- each |
Rs.250.000 Millions |
|
|
|
|
|
Issued :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
21560000 |
Equity Shares |
Rs.10/- each |
Rs.215.600
Millions |
|
|
|
|
|
Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
21040600 |
Equity Shares |
Rs.10/- each |
Rs.210.406
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
210.406 |
210.406 |
210.406 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
767.879 |
762.594 |
753.555 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
978.285 |
973.000 |
963.961 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
105.126 |
93.989 |
80.838 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
105.126 |
93.989 |
80.838 |
|
|
DEFERRED TAX LIABILITIES |
2.234 |
2.278 |
5.073 |
|
|
|
|
|
|
|
|
TOTAL |
1085.645 |
1069.267 |
1049.872 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
92.092 |
113.690 |
116.271 |
|
|
Capital work-in-progress |
642.607 |
603.553 |
481.049 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.000 |
90.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
155.416
|
162.703 |
170.829
|
|
|
Sundry Debtors |
214.143
|
228.779 |
387.188
|
|
|
Cash & Bank Balances |
1.494
|
10.351 |
10.590
|
|
|
Other Current Assets |
131.213
|
97.408 |
6.192
|
|
|
Loans & Advances |
63.111
|
78.375 |
70.929
|
|
Total
Current Assets |
565.377
|
577.616 |
645.728 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
155.485
|
184.543 |
331.786
|
|
|
Other Current Liabilities |
50.822
|
36.147 |
12.107
|
|
|
Provisions |
8.124
|
4.902 |
9.717
|
|
Total
Current Liabilities |
214.431
|
225.592 |
353.610 |
|
|
Net Current Assets |
350.946
|
352.024 |
292.118
|
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
70.434 |
|
|
|
|
|
|
|
|
TOTAL |
1085.645 |
1069.267 |
1049.872 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
551.299 |
828.673 |
934.367 |
|
|
|
Other Income |
5.406 |
7.448 |
8.949 |
|
|
|
TOTAL (A) |
556.705 |
836.121 |
943.316 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of Materials Consumed |
372.123 |
709.077 |
|
|
|
|
Purchases of Stock in Trade |
28.504 |
0.000 |
|
|
|
|
Manufacturing and Operating Cost |
30.364 |
27.628 |
|
|
|
|
Changes in Inventories of Finished Goods, Work in Progress and Stock in
Trade |
0.251 |
(5.905) |
|
|
|
|
Employee Benefits Expenses |
45.365 |
39.661 |
|
|
|
|
Other Expenses |
48.991 |
40.788 |
|
|
|
|
TOTAL (B) |
525.598 |
811.249 |
917.951 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
31.107 |
24.872 |
25.365 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
12.721 |
2.956 |
3.481 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
18.386 |
21.916 |
21.884 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
10.031 |
11.097 |
11.739 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
8.355 |
10.819 |
10.145 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
3.071 |
1.780 |
2.180 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
5.284 |
9.039 |
7.965 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
212.989 |
203.950 |
195.985 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
218.273 |
212.989 |
203.950 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export of goods on FOB Basis |
100.028 |
72.451 |
97.303 |
|
|
TOTAL EARNINGS |
100.028 |
72.451 |
97.303 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
18.002 |
9.781 |
4.640 |
|
|
|
Capital Goods |
9.886 |
21.513 |
0.000 |
|
|
TOTAL IMPORTS |
27.888 |
31.294 |
4.640 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
0.25 |
0.43 |
0.38 |
|
QUARTERLY RESULTS
|
PARTICULARS |
30.06.2012 |
30.09.2012 |
31.12.2012 |
|
Type |
1st
Quarter |
2nd
Quarter |
3rd
Quarter |
|
Net Sales |
132.200 |
119.300 |
120.200 |
|
Total Expenditure |
124.600 |
116.100 |
113.700 |
|
PBIDT (Excl OI) |
7.600 |
3.200 |
6.500 |
|
Other Income |
3.000 |
0.300 |
1.600 |
|
Operating Profit |
10.600 |
3.400 |
8.100 |
|
Interest |
3.000 |
4.500 |
6.700 |
|
Exceptional Items |
0.000 |
0.000 |
0.000 |
|
PBDT |
7.500 |
(1.100) |
1.400 |
|
Depreciation |
3.100 |
2.300 |
19.600 |
|
Profit Before Tax |
4.400 |
(3.400) |
(18.100) |
|
Tax |
0.000 |
0.800 |
0.000 |
|
Provisions and contingencies |
0.000 |
0.000 |
0.000 |
|
Profit After Tax |
4.400 |
(4.200) |
(18.100) |
|
Extraordinary Items |
0.000 |
0.000 |
0.000 |
|
Prior Period Expenses |
0.000 |
0.000 |
0.000 |
|
Other Adjustments |
0.000 |
0.000 |
0.000 |
|
Net Profit |
4.400 |
(4.200) |
(18.100) |
KEY RATIOS
|
PARTICULARS |
|
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
PAT / Total Income |
(%) |
0.95 |
1.08 |
0.84
|
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
1.52 |
1.31 |
1.09
|
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
1.27 |
1.57 |
1.33
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.01 |
0.01 |
0.01
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
0.11 |
0.10 |
0.08
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.64 |
2.56 |
1.83
|
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info
Agents |
Available in Report
(Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
No |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
Date of Birth of Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
No |
FINANCIAL RESULTS
The Company posted a turnover of Rs. 556.705 Millions for the Financial Year and earned a profit of Rs. 5.284 Millions. The exercise of product consolidation and pruning of the product line has resulted in a further improvement in the profitability of the Company during the year. Even in the difficult market, the Company has continued to book a profit as a result of better management, cost efficiencies and strategic planning or margin. WHO-GMP certification has been renewed for the old plant and WHO-GMP certification has also been granted to the new plant. Further, the new plant has taken several pilot and exhibit batches and the results have been very satisfactory.
MANAGEMENT REVIEW:
Industry Structure
and Development:
There has been a general uncertainty across the world due to repeated economic and civic events. Besides a continuing economic turmoil across the world, major civic events are taking place in the middle east and other parts of the world. Although India has been playing an increasing important role in the world economy, it has also seen reduced growth and has not been able to deliver on projections and expectations.
Despite such adverse conditions, the Company has fared fairly well. Profitability has improved and the management believes that the Company is at a point of upward inflection in yielding better results for its stakeholders.
Manufacturing
Facilities:
The Company already has a state of the art WHO-GMP certified manufacturing facility at Pigdamber, Indore (Unit-I) where it manufactures a wide range of dosage forms like Injections, Tablets, Ointments and Capsules. An up-gradation of the existing facility in terms of cGMP norms and expansion of capacities has recently been completed. At present the Company is tapping the domestic market, export markets like East and West Africa, Latin America, South East Asia and domestic and international Government Tender business from this facility. The Company also has a state of the art testing laboratory. The new regulated market compliant oral solid dosage manufacturing facility focusing on containment products such as oral hormonal and other oral hi-potency formulations at the Pithampur Industrial Area (Unit-II) has become operational and already has received its WHO-GMP certification. Unit-II is equipped with world class manufacturing and testing equipment is rapidly progressing to commercial fruition. This state of the art plant is compliant to the most rigorous regulatory requirements from anywhere in the world and specifically designed and engineered for the manufacture of hormonal and other hi-potency oral solid dosages. During the current year, it is expected to contribute substantially to the financial performance of the Company.
Regulatory Approvals:
Unit-I continues to enjoy the approval of major international regulatory agencies and several dosage forms are being manufactured for export. This WHO-GMP certification of the plant has also been renewed. Unit-II has received its WHO-GMP certification and is well on its way offer its facility for various other regulatory approvals including USFDA, UKMHRA, EU Approval.
Domestic Markets:
The Company has a wide range of pharmaceutical products in its portfolio. A focused approach and increased marketing efforts has resulted in an increasingly wider reach. In the coming years, the Company would continue to build its reputation and strong brand equity in order to attain a leadership position. The Company has been successfully marketing human products through a generics distribution model.
International
Markets:
The Company continues to lay emphasis on its overseas business. The Company works closely with all its overseas partners to sustain and grow its exports. In the last financial year, the Company has expanded its operations in South East Asia, Africa and Latin America. With the commercial production expected to start soon at Unit-II, the Company will be ready to take a leap into the regulated markets.
Outlook:
The Company remains optimistic about the bright future lying ahead. It will endeavor to grow by building on its strengths for competitive advantage. The Domestic business is becoming more competitive with the entry of newer players from the emerging economies. On the other hand, the government induced changes in select markets and the ongoing consolidation in the industry is bringing forth new challenges in the market place. The generic segment has inherent risks of patent litigation, product liability, continuous development in R and D, capital investment, increasing regulations and compliance related issues, particularly in the developed markets.
CONTINGENT LIABILITIES
(Rs. In Millions)
|
Particular |
31.03.2012 |
31.03.2011 |
|
Bank Guarantees given to various government departments for tenders |
6.207 |
6.258 |
|
Bank Guarantees given to Deputy Commissioner of Customs against import of capital goods under Export Promotion Capital Scheme for a period of the years ending 09.02.2020 |
1.785 |
1.785 |
|
Disputed demand of Value Added Tax |
3.667 |
4.840 |
|
Disputed demand of Central Sales Tax |
6.632 |
4.731 |
|
Disputed demand of Entry Tax |
0.000 |
4.530 |
FIXES ASSETS:
· Land and Site Development
· Building
· Plant and Machinery
· Furniture and Fixture
· Computers
· Utility
· Electrical Installation
· QC and Lab. Equipment
· Office Equipment
FINANCIAL RESULTS FOR QUARTER ENDED 31ST
DECEMBER, 2012
(Rs. in millions)
|
Particulars |
Quarter Ended 31.12.2012 |
Quarter Ended 30.09.2012 |
6 Months Ended
31.12.2012 |
|
Unaudited |
Unaudited |
Unaudited |
|
|
|
|
|
|
|
(a) Net sales/income from
operations |
116.855 |
116.724 |
363.412 |
|
(b) Other operating income |
3.328 |
2.555 |
7.089 |
|
1. Total
income front operations (net) (a + b) |
120.183 |
119.279 |
370.501 |
|
(e) Cost of materials consumed |
86.395 |
85.002 |
264.214 |
|
(d) Purchases of stock-in-trade |
0.000 |
0.000 |
0.000 |
|
(e) Changes in inventories of fin.
goods, stock-in-pro. & stock-in-trade |
(15.118) |
(4.693) |
(22.218) |
|
(f) Employee benefits expense |
18.022 |
12.781 |
42.479 |
|
(g) Depreciation and amortization
expense |
19.549 |
2.316 |
24.111 |
|
(h) Other expenses |
24.379 |
23.028 |
69.433 |
|
2.Total expenses (c+d+e+f+g-H) |
133.227 |
118.435 |
378.017 |
|
3. Profit/ Loss(-) from operations
before other income and finance costs (1-2) |
(13.044) |
0.845 |
(7.516) |
|
4. Other Income |
1.588 |
0.266 |
4.818 |
|
5. Profit/ Loss(-) from ordinary activities before finance costs (3+4) |
(11.455) |
1.111 |
(2.698) |
|
6. Finance costs |
6.685 |
4.503 |
14.220 |
|
7. Profit/ Loss(-) from ordinary activities before Tax (5-6) |
(18.141) |
(3.393) |
(16.919) |
|
8. Tax expense |
0.000 |
0.776 |
0.776 |
|
9. Net Profit/ Loss(-) from ordinary
activities after tax {9-10) |
(18.141) |
(4.169) |
(17.695) |
|
10. Paid-up equity snare capital
[Face Value Rs.10 Each] |
210.406 |
210.406 |
210.406 |
|
11. Reserves excluding Revaluation
Reserves as per bal. sheet of prey, year |
|
|
|
|
12. Basic and Dinted Earnings per
share in Rs. (not annualized) |
(0.86) |
(0.20) |
(0.84) |
|
13. Public
shareholding |
|
|
|
|
- Number of shares |
10319030 |
10319030 |
10319030 |
|
- Percentage of shareholding |
49.04% |
49.04% |
49.04% |
|
14. Promoter and Promoter Group Shareholding |
|
|
|
|
a) Pledged /
Encumbered |
|
|
|
|
- Number of
Shares |
-- |
-- |
-- |
|
- Percentage of
Shares (as a % of total shareholding of promoter & promoter group) |
-- |
-- |
-- |
|
- Percentage of
Shares (as a % of total share capital of the Company) |
-- |
-- |
-- |
|
b) Non-Encumbered |
|
|
|
|
- Number of
Shares |
10721570 |
10721570 |
10721570 |
|
- Percentage of
Shares (as a % of total shareholding of promoter & promoter group) |
100.00% |
100.00% |
100.00% |
|
- Percentage of
Shares (as a % of total share capital of the Company) |
50.96% |
50.96% |
50.96% |
INVESTOR COMPLAINTS:
|
B. Investor Complaints: |
|
|
|
|
|
Pending at the start of the quarter |
0 |
|
Received during the quarter |
5 |
|
Investor Complaints: |
|
|
|
|
|
Disposed off during the quarter |
5 |
|
Unresolved till end of the quarter |
0 |
Notes :
1, The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today
2, The Company is operating in the single segment of Drugs and Chemicals,
3, The Provision for Tax may not have been made for the partial/ unaudited periods.
4, The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.65 |
|
|
1 |
Rs.82.66 |
|
Euro |
1 |
Rs.71.21 |
INFORMATION DETAILS
|
Report Prepared
by : |
BSN/ VRN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
3 |
|
OPERATING SCALE |
1~10 |
4 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
4 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
4 |
|
--CREDIT LINES |
1~10 |
4 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
32 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.